Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00258271 · ClinicalTrials.gov registry record · Phase 1
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00258271 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 18 participants.
The verdict
NCT00258271, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cladribine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cladribine and cytarabine together with imatinib mesylate may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with cladribine and cytarabine in treating patients with refractory or relapsed acute myeloid leukemia or blastic phase chronic myelogenous leukemia.
Interventions
- DRUG imatinib mesylate
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG cladribine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00258271
The ClinicalTrials.gov registry entry for NCT00258271 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which imatinib mesylate is the first listed.
NCT00258271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00258271 about?
NCT00258271 is a clinical study titled "Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy, such as cladribine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell gr...
What is the current status of trial NCT00258271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2005-03. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00258271?
The interventions under investigation include: imatinib mesylate (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), cladribine (DRUG).
Who is sponsoring clinical trial NCT00258271?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.